converting concept into product

Discovering opportunities, accelerating development and partnering wisely

Why Greenfire

How we build success

Medical innovations are precious and exciting and come from all over. Making a good idea in medicine into a product is a difficult and expensive process. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.

That’s where Greenfire comes in. We have assembled experts, advisors, service providers, and capital to deploy on late pre-clinical and early clinical assets to accelerate their development into products.

Our extensive network seeks out exciting innovations, engages flexibly with the innovators, and accelerates the transition to medical products. We take the unappreciated risks out of development – timely access to expertise and capital. If you think you have an innovation that fits our profile, contact us.

And when a product is ready for the last steps for approval and commercialization, our team has deep experience in navigating the right path to optimize success and return for all participants.

Opportunity Access

Capitalize on access to innovative preclinical and early-stage clinical products and technology

Development Acceleration

Leverage an integrated ecosystem of development organizations and internal expertise to accelerate product development timelines

Business MONETIZATION

Monetize investments through strategic and well-timed out-licensing, sale or IPO of each product to provide liquidity to investors and the best path to bringing products to patients

Our process sounds simple but execution is where we excel

Acquire pipeline of differentiated products to meet underserved medical needs. If you think you have an innovation that fits our profile, contact us.

Deploy very experienced biopharma team for efficient drug development and business management

Utilize a successful organizational model; leverage virtual operations focused program management and partner ecosystem of service providers

Exit programs after advancing candidates to an appropriate value inflection point

Provide excellent returns to investors by delivering superior products to patients

MANAGEMENT TEAM

Ajit Gill

CEO and Founder, Director

CEO & President Nektar Therapeutics
VP and Gen Mgr Kodak’s Interactive Systems
VP Finance at TRW-Fujitsu

Steve Morris, MD

CMO

CEO & Internist/Medical Oncologist
Former PI: St Jude’s (discovered ALK, developed ALK CDx and inhibitors)

Michael Weickert, PhD

COO

CEO at Pacylex, Sonescence, SEA Med., COO Therashock, drug development at Ligand, Nektar, Auspex, NIH / NCI

Sanjeev Munshi, PHD, MBA

CBO

SVP, BD & Alliance Management, InveniAI
Ex. Director Merck BD and Discovery

Shailaja Gupta,PhD

Executive Director, CMC

Vikas Agarwal, PhD

VP Program Management

Gayathri Swaminath, PHD, MBA

VP Research

BOARD OF DIRECTORS

Purnanand Sarma, PhD

CEO Immunome
CEO Taris
GM Cephalon
VP Nektar

Ajit Gill

Director

Chris Searcy, PharmD

CBO Nocion
CBO Respira
CBO Taris
VP Valeritas, Nektar, Pfizer

Hong-Min Suh

Chair, M2N
CEO, DK Marine
Chair, The LEADCORP

Kevin Yang

CEO Korea Solar
Bear Sterns

PIPELINE

Making a fast start to building an innovative pipeline, agnostic to therapeutic areas, we are addressing serious unmet medical needs.
If you think you have an innovation that fits this portfolio, contact us.

*Click for more information about portfolio candidates

Product Company Target Indication Therapeutic Area Discovery Preclinical Clinical
In Vitro In vivo Lead up IND Enabling Phase 1 Phase 2
GRN-300 Green3bio SIK2, SIK3 inhibitor Ovarian cancer Oncology
PCLX-001 Pacylex NMT1, NMT2 inhibitor Hematologic malignancies Oncology
Mid-2021
WT-001 WeaveTech Wound Repair Urethral strictures Urology
1Q2022

Questions?   We’ve got answers!

Latest Articles

Greenfire Bio Announces the Creation of WeaveTech

Greenfire Bio Announces the Creation of WeaveTech

Tissue Repair Using Silk Based Technology Austin TX, June 22, 2021 -- Greenfire Bio, LLC announced today that it has formed a new subsidiary, WeaveTech, to research and develop bi-layer silk fibroin (BLSF) scaffolds to repair visceral hollow organ defects. Successful feasibility studies in...

read more

Get in touch